Treatment of multiple myeloma with renal involvement: The nephrologist's view

11Citations
Citations of this article
60Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Renal injury is a common complication in multiple myeloma (MM). In fact, as many as 10% of patients with MM develop dialysis-dependent acute kidney injury related to increased free light chain (FLC) production by a plasma cell clone. Myeloma cast nephropathy (MCN) is the most prevalent pathologic diagnosis associated with renal injury, followed by light chain deposition disease and light chain amyloidosis. Several FLC removal techniques have been explored to improve kidney disease in MM but their impact on renal clinical outcomes remains unclear. According to the evidence, high cut-off haemodialysis should be restricted to MM patients on chemotherapy with histological diagnosis of MCN and haemodialysis requirements. From our perspective, more efforts are needed to improve kidney outcomes in patients with MM and renal failure.

Cite

CITATION STYLE

APA

Favà, A., Fulladosa, X., Montero, N., Draibe, J., Torras, J., Gomà, M., & Cruzado, J. M. (2018). Treatment of multiple myeloma with renal involvement: The nephrologist’s view. Clinical Kidney Journal, 11(6), 777–785. https://doi.org/10.1093/ckj/sfy065

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free